Financial Performance - The company achieved total operating revenue of 621.34 million yuan, a year-on-year increase of 29.98%[2] - Net profit attributable to the parent company reached 245.69 million yuan, reflecting a year-on-year growth of 41.24%[5] - The net profit excluding non-recurring gains and losses grew by 47.52% year-on-year, reaching 216.93 million yuan[9] - Basic earnings per share increased by 41.41% to 1.81 yuan[2] - The increase in operating profit by 37.12% and total profit by 38.50% is attributed to favorable market conditions in the respiratory testing sector[9] Assets and Returns - The company's total assets at the end of the reporting period were 2.22 billion yuan, an increase of 7.33% from the beginning of the period[5] - The weighted average return on net assets rose to 12.67%, an increase of 2.8 percentage points compared to the previous year[2] Strategic Initiatives - The company plans to enhance its core competitive advantages by increasing investments in channel network construction and international market access[7] - The company is focusing on digital and intelligent upgrades to improve operational efficiency and risk control capabilities[7] Cautionary Note - The company warns that the financial data presented are preliminary and subject to final audit, urging investors to be cautious[10]

证券代码：688253 证券简称：英诺特 公告编号：2025-004 北京英诺特生物技术股份有限公司 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机拟用于 员工持股计划/或股权激励。公司本次回购价格不超过人民币 50.00 元/股（含），回 购股份金额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回 购股份的实施期限自董事会审议通过本次回购方案之日起 12 个月内。具体内容详 见公司于 2024 年 8 月 3 日在上海证券交易所网站（www.sse.com.cn）披露的《关 于以集中竞价方式回购公司股份方案的公告》（公告编号：2024-030）及 2024 年 8 月 8 日披露的《关于以集中竞价方式回购股份的回购报告书》（公告编号：2024-035）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定， ...

| 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 个月 12 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 158.7406 万股 | | 累计已回购股数占总股本比例 | 1.1633% | | 累计已回购金额 | 万元 6,201.26 | | 实际回购价格区间 | 元/股~45.37 元/股 28.62 | 证券代码：688253 证券简称：英诺特 公告编号：2025-003 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股 本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定 ...

Financial Projections - The company expects to achieve an annual operating revenue of approximately RMB 621.34 million for 2024, representing a year-on-year growth of about 29.98%[3] - The projected net profit attributable to shareholders for 2024 is approximately RMB 245.70 million, reflecting a year-on-year increase of about 41.25%[3] - In 2023, the company reported an operating revenue of RMB 478.02 million and a net profit of RMB 173.95 million[5] Market Development - The growth in performance is attributed to the ongoing development of the national hierarchical medical system and increased awareness of early diagnosis and treatment among patients[6] - The company is actively expanding its market presence in both tiered hospitals and grassroots medical markets[6] Financial Data Disclaimer - The financial data provided in the forecast has not been audited by a registered accountant[4] - Investors are advised that the forecast data is preliminary and the final figures will be disclosed in the official 2024 annual report[8] - The company emphasizes the importance of recognizing investment risks associated with the preliminary financial data[8]

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-014 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | 投资者关系活 动类别 | £ □ | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ...

呼吸道系列产品增长迅速，海外市场可期 证 券 研 究 报 告 ——英诺特 2024 年三季报业绩点评 公 司 研 究 公 司 点 评 ◼ 事件描述 公司发布 2024 年三季度报告, 业绩快速增长：2024 年前三季度收入 约 5.21 亿元，同比增长 87.05%；归母净利润约 2.45 亿元，同比增长 182.65%；扣非归母净利润约 2.24 亿元，同比增长 239.12%。前三季 度公司毛利率、归母净利率、扣非归母净利率分别为 81.0%、47.0%、 43.0%，分别提升 9.35 个百分点、15.88 个百分点、19.27 个百分点。 24Q3 毛利率、归母净利率、扣非归母净利率分别为 78.2%、38.4%、 32.5%，同比提升 3.69 个百分点、21.8 个百分点、26.41 个百分点。 ◼ 核心观点 呼吸道系列非新冠产品增长迅速：公司业务主要由呼吸道系列-非新冠 产品构成，据财报显示，2023 年该业务收入占比约 84.83%，到 2024 年上半年，该占比更是高达 97.74%；公司产品主要包括全血呼吸五项 检测试剂盒、流感抗原三项检测试剂盒、流感抗体三项检测试剂盒， 等等。2024 ...

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-013 | --- | --- | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ☑路演活动 现场参观 □其他（券商策略会） | | 参与单位名称 及人员姓名 | 三头牛基金：林伟杰；嘉强私募：王子帅；银国达资本：梁志安；明勤基 金：朱一平； ...

证券代码：688253 证券简称：英诺特 公告编号：2024-056 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 118.6052 | | 累计已回购股数占总股本比例 | 0.8692% | | 累计已回购金额 | 5,001.26 万元 | | 实际回购价格区间 | 35.93 元/股~45.37 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-055 北京英诺特生物技术股份有限公司关于认购私募基 金份额暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 / 2 市公司重大资产重组管理办法》规定的重大资产重组。减资完成后，泓创海河出 资额合计为 20,613.00 万元，景达广源认缴出资 1,250.00 万元，认缴出资占基金 总认缴出资额的比例降低至 6.06%。 三、其他事项 一、对外投资暨关联交易概述 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2023 年 11 月 30 日召开第二届董事会第二次会议、第二届监事会第二次会议，同意公司之全资子 公司北京景达广源科技发展有限公司（以下简称"景达广源"）作为天津泓创海 河创业投资合伙企业（有限合伙）（以下简称"泓创海河"）之有限合伙人，以自 有资金认缴出资人民币 2,000.00 万元，出资比例占基金总认缴出资额的 11.80%。 具 体 内 容 详 见 公 司 于 2023 年 12 月 2 日 在 上 海 证 券 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights steady improvement in market penetration and anticipates significant growth in both domestic and overseas markets in the fourth quarter [1] - The company reported a total revenue of 521 million yuan for the third quarter, representing an increase of 87.05%, with a net profit attributable to the parent company of 245 million yuan, up 182.65% [1] - The report emphasizes that the profit growth rate significantly outpaces revenue growth, with a notable increase in core revenue driven by the rise in respiratory multi-detection products [1] Summary by Sections Financial Performance - For the third quarter, the company achieved a revenue of 521 million yuan, with a net profit of 245 million yuan, and a non-recurring net profit of 224 million yuan, reflecting increases of 87.05%, 182.65%, and 239.12% respectively [1] - The company’s core revenue showed a rapid growth trend, with a year-on-year increase of 250% [5] Future Outlook - The third quarter is viewed as a turning point for annual revenue, with expectations for rapid growth in the fourth quarter driven by increased demand for respiratory multi-detection products [1] - The company has received approvals for two multi-detection products in Malaysia and Myanmar, which cover 15 types of respiratory pathogens, indicating strong potential for market expansion [1] Financial Projections - The company is projected to achieve revenue growth rates of 67.8%, 41.7%, and 34.6% for the years 2024, 2025, and 2026 respectively, with net profits expected to reach 396 million yuan, 569 million yuan, and 758 million yuan in the same years [5][6] - The report forecasts an increase in gross margin from 76.0% in 2023 to 88.3% in 2024, indicating improved profitability [5]